Reach Us +1-504-608-2390
Human ?d T Cell Responses To Infections And Cancer: From Basic Immunology To Immunotherapy | 3230
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Human ?d T cell responses to infections and cancer: From basic immunology to immunotherapy

Marc Bonneville

: J Vaccines Vaccin

Vγ9Vδ2 T lymphocytes are a major γδ T cell subset in adults that makes up 0.5 to 5 % of the peripheral lymphoid pool. Vγ9Vδ2 T cells recognize a broad set of activated, transformed or infected cells in vitro. Accordingly they are expanded in vivo in a variety of infectious or tumor contexts. This broad reactivity pattern is primarily accounted for by recognition of small non- peptidic phosphorylated compounds, referred to as ? phosphoantigens ? (P-Ag), that correspond to metabolites of the isoprenoid biosynthetic pathway used by both mammalian cells and micro-organisms. How exactly P-Ag are sensed by Vγ9Vδ2 T cells remains unknown. I will present recent unpublished result showing a unique and mandatory role played by a new member of the extended B7 receptor family in this activation process. From a more applied standpoint, the broad antimicrobial and antitumor reactivity of Vγ9Vδ2 cells, their strong cytolytic and bactericidal activities, and their ability to produce inflammatory cytokines suggest a protective role played in infectious and tumor immunity. These observations, together with the recent availability of clinical grade compounds able to activate Vγ9Vδ2 T cells in vitro and in vivo, have fostered development of immunotherapeutic strategies targeting this lymphoid subset in various clinical settings. I will review the latest results from immunotherapeutic trials in cancer and chronic infections, that rely on either adoptive transfer of in vitro expanded autologous Vγ9Vδ2 T cells or in vivo treatment with clinical grade Vγ9Vδ2 T cell agonists.
Marc Bonneville has completed his postdoctoral studies from MIT (Cambridge, MA) in 1989, and has been heading since then a team working on human cellular immunity within a Cancer Research Center in Nantes (France). He co-founded in 1999 the biotech company Innate Pharma SA, which implements new immunotherapies targeting innate lymphocytes in infectious diseases and cancer. M.B. is author of more than 200 peer- reviewed papers (including Nature, Science, Cell, PNAS, Immunity,...) and 8 patents. He has received several awards (Bronze and Silver CNRS medal, Halpern and LNCC prizes), and has been involved in more than 30 scientific councils.